SCHOLAR ROCK HOLDING CORP (SRRK) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SRRK • US80706P1030

47.25 USD
-0.7 (-1.46%)
Last: Feb 4, 2026, 11:18 AM
Fundamental Rating

2

SRRK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. While SRRK seems to be doing ok healthwise, there are quite some concerns on its profitability. SRRK has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • SRRK had negative earnings in the past year.
  • SRRK had a negative operating cash flow in the past year.
  • In the past 5 years SRRK always reported negative net income.
  • SRRK had a negative operating cash flow in each of the past 5 years.
SRRK Yearly Net Income VS EBIT VS OCF VS FCFSRRK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

  • The Return On Assets of SRRK (-85.84%) is worse than 70.61% of its industry peers.
  • The Return On Equity of SRRK (-144.26%) is worse than 63.36% of its industry peers.
Industry RankSector Rank
ROA -85.84%
ROE -144.26%
ROIC N/A
ROA(3y)-47.57%
ROA(5y)-41.66%
ROE(3y)-64.04%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
SRRK Yearly ROA, ROE, ROICSRRK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SRRK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRRK Yearly Profit, Operating, Gross MarginsSRRK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

5

2. Health

2.1 Basic Checks

  • SRRK has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, SRRK has more shares outstanding
  • The debt/assets ratio for SRRK has been reduced compared to a year ago.
SRRK Yearly Shares OutstandingSRRK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRRK Yearly Total Debt VS Total AssetsSRRK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 11.55 indicates that SRRK is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 11.55, SRRK belongs to the best of the industry, outperforming 83.40% of the companies in the same industry.
  • SRRK has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
  • SRRK has a Debt to Equity ratio of 0.41. This is in the lower half of the industry: SRRK underperforms 69.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 11.55
ROIC/WACCN/A
WACCN/A
SRRK Yearly LT Debt VS Equity VS FCFSRRK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

  • A Current Ratio of 6.30 indicates that SRRK has no problem at all paying its short term obligations.
  • SRRK's Current ratio of 6.30 is fine compared to the rest of the industry. SRRK outperforms 64.50% of its industry peers.
  • A Quick Ratio of 6.30 indicates that SRRK has no problem at all paying its short term obligations.
  • SRRK's Quick ratio of 6.30 is fine compared to the rest of the industry. SRRK outperforms 65.46% of its industry peers.
Industry RankSector Rank
Current Ratio 6.3
Quick Ratio 6.3
SRRK Yearly Current Assets VS Current LiabilitesSRRK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

1

3. Growth

3.1 Past

  • SRRK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -34.47%.
EPS 1Y (TTM)-34.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SRRK is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.62% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-42.26%
EPS Next 2Y-15.45%
EPS Next 3Y3.21%
EPS Next 5Y17.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SRRK Yearly Revenue VS EstimatesSRRK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2019 2020 2021 2022 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
SRRK Yearly EPS VS EstimatesSRRK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6

0

4. Valuation

4.1 Price/Earnings Ratio

  • SRRK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRRK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRRK Price Earnings VS Forward Price EarningsSRRK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRRK Per share dataSRRK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.45%
EPS Next 3Y3.21%

0

5. Dividend

5.1 Amount

  • SRRK does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

SCHOLAR ROCK HOLDING CORP

NASDAQ:SRRK (2/4/2026, 11:18:53 AM)

47.25

-0.7 (-1.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)02-25
Inst Owners119.13%
Inst Owner Change-0.9%
Ins Owners3.18%
Ins Owner Change-1.2%
Market Cap4.82B
Revenue(TTM)N/A
Net Income(TTM)-353.43M
Analysts87
Price Target50.34 (6.54%)
Short Float %15.98%
Short Ratio12.47
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.88%
Min EPS beat(2)-44.57%
Max EPS beat(2)-5.19%
EPS beat(4)2
Avg EPS beat(4)-12.09%
Min EPS beat(4)-44.57%
Max EPS beat(4)0.74%
EPS beat(8)3
Avg EPS beat(8)-8.36%
EPS beat(12)7
Avg EPS beat(12)-1%
EPS beat(16)10
Avg EPS beat(16)5.37%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.01%
PT rev (3m)5.92%
EPS NQ rev (1m)-0.44%
EPS NQ rev (3m)-10.24%
EPS NY rev (1m)0.19%
EPS NY rev (3m)-4.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-9.09%
Revenue NY rev (3m)-94.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 19.67
P/tB 19.67
EV/EBITDA N/A
EPS(TTM)-3.16
EYN/A
EPS(NY)-3.28
Fwd EYN/A
FCF(TTM)-2.7
FCFYN/A
OCF(TTM)-2.69
OCFYN/A
SpS0
BVpS2.4
TBVpS2.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.84%
ROE -144.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.57%
ROA(5y)-41.66%
ROE(3y)-64.04%
ROE(5y)-60.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.07%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.3
Quick Ratio 6.3
Altman-Z 11.55
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)14.34%
Cap/Depr(5y)103.43%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.36%
EPS Next Y-42.26%
EPS Next 2Y-15.45%
EPS Next 3Y3.21%
EPS Next 5Y17.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-57.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-60.67%
EBIT Next 3Y16.59%
EBIT Next 5YN/A
FCF growth 1Y-100.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.68%
OCF growth 3YN/A
OCF growth 5YN/A

SCHOLAR ROCK HOLDING CORP / SRRK FAQ

What is the fundamental rating for SRRK stock?

ChartMill assigns a fundamental rating of 2 / 10 to SRRK.


What is the valuation status for SRRK stock?

ChartMill assigns a valuation rating of 0 / 10 to SCHOLAR ROCK HOLDING CORP (SRRK). This can be considered as Overvalued.


How profitable is SCHOLAR ROCK HOLDING CORP (SRRK) stock?

SCHOLAR ROCK HOLDING CORP (SRRK) has a profitability rating of 0 / 10.


What is the expected EPS growth for SCHOLAR ROCK HOLDING CORP (SRRK) stock?

The Earnings per Share (EPS) of SCHOLAR ROCK HOLDING CORP (SRRK) is expected to decline by -42.26% in the next year.